Abstract
A series of 3-[(2,4-dioxothiazolidin-5-yl)methyl]benzamide derivatives was prepared as part of a search for antidiabetic agents. A structure- activity relationship study of these compounds led to the identification of 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[4- (trifluoromethyl)phenyl]methyl]benzamide (KRP-297) as a candidate drug for the treatment of diabetes mellitus.
| Original language | English |
|---|---|
| Pages (from-to) | 533-538 |
| Number of pages | 6 |
| Journal | Bioorganic and Medicinal Chemistry Letters |
| Volume | 9 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Feb 22 1999 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry
- Molecular Biology
- Organic Chemistry
- Drug Discovery
- Pharmaceutical Science
Cite this
(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents. / Nomura, Masahiro; Kinoshita, Susumu; Satoh, Hiroya; Maeda, Toshio; Murakami, Koji; Tsunoda, Masaki; Miyachi, Hiroyuki; Awano, Katsuya.
In: Bioorganic and Medicinal Chemistry Letters, Vol. 9, No. 4, 22.02.1999, p. 533-538.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - (3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents
AU - Nomura, Masahiro
AU - Kinoshita, Susumu
AU - Satoh, Hiroya
AU - Maeda, Toshio
AU - Murakami, Koji
AU - Tsunoda, Masaki
AU - Miyachi, Hiroyuki
AU - Awano, Katsuya
PY - 1999/2/22
Y1 - 1999/2/22
N2 - A series of 3-[(2,4-dioxothiazolidin-5-yl)methyl]benzamide derivatives was prepared as part of a search for antidiabetic agents. A structure- activity relationship study of these compounds led to the identification of 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[4- (trifluoromethyl)phenyl]methyl]benzamide (KRP-297) as a candidate drug for the treatment of diabetes mellitus.
AB - A series of 3-[(2,4-dioxothiazolidin-5-yl)methyl]benzamide derivatives was prepared as part of a search for antidiabetic agents. A structure- activity relationship study of these compounds led to the identification of 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[4- (trifluoromethyl)phenyl]methyl]benzamide (KRP-297) as a candidate drug for the treatment of diabetes mellitus.
UR - http://www.scopus.com/inward/record.url?scp=0033593916&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033593916&partnerID=8YFLogxK
U2 - 10.1016/S0960-894X(99)00039-6
DO - 10.1016/S0960-894X(99)00039-6
M3 - Article
C2 - 10098657
AN - SCOPUS:0033593916
VL - 9
SP - 533
EP - 538
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
SN - 0960-894X
IS - 4
ER -